慢性丙型肝炎患者血清自身抗体检测及其临床意义研究现状*

doi:10.3969/j.issn.1672-5069.2018.05.045

Abstract

Abstract: Serum non-organ-specific autoantibodies（NOSA） and anti-thyroid autoantibodies（ATAB） were often found positive in patients with chronic hepatitis C and hepatitis C viral carriers. The patients were characterized by loss of autoimmune tolerance, which might cause a set of autoimmune diseases in this setting. The progress in this field will be discussed in this article.

Key words: Hepatitis C, Autoimmunity, Antinuclear antibodie, Autoimmune thyroid diseases, Interferon-alpha

Jiang Hongda, Zhou Haizhou.. Serum autoantibodies in patients with hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 817-820.

References

[1] Ghany MG,Nelson DR,Strader DB,et al.An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology,2011,54:1433-1444.
[2] Czarnywojtek A,Zgorzalewicz-Stachowiak M,Wasko R,et al.Patients with chronic hepatitis type C and interferon-alpha-
induced hyperthyroidism in two-years clinical follow-up. Neuro Endocrinol Let,2013,34:154-161.
[3] Marconcini ML,Fayad L,Shiozawa MB,et al.Autoantibody profile in individuals with chronic hepatitis C. Rev Soc Bras Med Trop,2013,46:147-153.
[4] Huang JF,Huang CK,Yu ML,et al.Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. Hepatol Int,2011,6:613-619.
[5] Shao C,Huo N,Zhao L,et al.The presence of thyroid peroxidase antibody of IgG2 subclass is a risk factor for thyroid dysfunction in chronic hepatitis C patients. Eur J Endocrinol,2013,168:717-722.
[6] Daschakraborty S,Aggarwal A,Aggarwal R.Non-organ-specific autoantibodies in Indian patients with chronic liver disease. Indian J Gastroenterol, 2012,31:237-242.
[7] Dalgard O,Bj ro K,Hellum K,et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha:no association with either interferon dosage or efficacy of therapy. J Intern Med,2002,251:400-406.
[8] Wong V,Fu AX,George J,et al.Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf),2002,56:793-798.
[9] Hsieh MY,Dai CY,Lee LP,et al.Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients. Kaohsiung J Med Sci,2012,28:86-93.
[10] Rigopoulou EI,Zachou K,Gatselis N,et al.Autoimmune hepatitis in patients with chronic HBV and HCV infections:patterns of clinical characteristics,disease progression and outcome. Ann Hepatol,2013,13:127-135.
[11] Zachou K,Muratori P,Koukoulis GK,et al.Review article:autoimmune hepatitis-current management and challenges. Aliment Pharmacol Ther,2013,38:887-913.
[12] EASL recommendations on treatment of hepatitis C 2014. C 2014. J Hepatol,2014,61:373-395.
[13] Kim SR,Imoto S,Kudo M,et al.Autoimmune thrombocytopenic purpura during pegylated interferon α treatment for chronic hepatitis C. Intern Med,2010,49:1119-1122.
[14] Mauss S,Berger F,Schober A,et al.Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome. J Viral Hepat,2013,20:e72-e77.
[15] Khairy M,El-Raziky M,El-Akel W,et al.Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response. Liver Int,2013,33:1504-1509.
[16] Gatselis NK,Georgiadou SP,Tassopoulos N,et al.Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection:a pilot study. World J Gastroenterol, 2005,11:482-487.
[17] De Luca A,Bianco C,Rossetti B.Treatment of HCV infection with the novel NS3/4A protease inhibitors. Curr Opin Pharmacol,2014,18:9-17.
[18] Yang R,Shan Z,Li Y,et al.Prevalence of thyroid autoantibodies in hepatitis C and hepatitis B infection in China. Intern Med,2011,50:811-815.
[19] Vanderpump MP.The epidemiology of thyroid disease. Br Med Bull,2011,99:39-51.
[20] Kozielewicz D,Halota W.Interferon-induced thyroiditis during treatment of chronic hepatitis C. Endokrynol Pol,2012,63:66-70.
[21] Barbesino G,Tomer Y.Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab,2013,98:2247-2255.
[22] Kozielewicz D,Halota W.Interferon-induced thyroiditis during treatment of chronic hepatitis C. Endokrynol Pol,2012,63:66-70.
[23] Antonelli A,Ferri C,Pampana A,et al.Thyroid disorders in chronic hepatitis C. Am J Med,2004,117:10-13.
[24] Rubio-Tapia A,Hill ID,Kelly CP,et al. ACG clinical guidelines:diagnosis and management of celiac disease. Am J Gastroenterol,2013,108:656-676,quiz 677.
[25] Preziati D,La Rosa L,Covini G,et al.Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol,1995,132:587-593.
[26] Wong V,Fu AX,George J,et al.Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf),2002,56:793-798.
[27] Paraná R,Cruz M,Santos-Jesus R,et al.Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin. Braz J Infect Dis,2000,4:284-290.
[28] Tran HA,Attia JR,Jones TL,et al.Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon alpha2beta in a hepatitis C population:Meta-analysis. J Gastroenterol Hepatol,2007,22:472-476.
[29] Tran HA,Jones TL,Ianna EA,et al.The natural history of interferon-α induced thyroiditis in chronic hepatitis c patients:a long term study. Thyroid Res,2011,4:2.
[30] Antonelli A,Ferri C,Fallahi P,et al.Thyroid disorders in chronic hepatitis C virus infection. Thyroid,2006,16:563-572.
[31] Nair Kesavachandran C,Haamann F,Nienhaus A.Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One,2013,8:e55364.
[32] Mandac JC,Chaudhry S,Sherman KE,et al.The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology,2006,43:661-672.

Serum autoantibodies in patients with hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Deng Haohui, Li Xiaoqiang, Gao Hongbo, et al. Comparison of HCV genotypes in patients with HIV/HCV co-infection and HCV mono-infection in Guangzhou [J]. Journal of Practical Hepatology, 2019, 22(5): 656-659.
[4]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[5]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[6]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[7]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[8]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[9]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[10]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.
[11]	Xu Xi, Dang Yinli, Wu Shuo.. Construction and expression of recombinant eukaryotic expression vector of HCV infection related interferon λ4 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 833-836.
[12]	Ji Xiaoqin, Gong Jian.. Clinical features and antiviral treatment of elderly patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 995-998.
[13]	Zhou Sisi, Shen Youxiu, Li Juan, et al.. Changes of peripheral blood Th17 and Treg cells and their related serum cytokines in patients with chronic hepatitis C and liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 689-692.
[14]	Cao Fenghua, Jing Jisheng, Zhao Wei, et al.. Clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 729-732.
[15]	Wang Jingjing, Zhang Yu, Dong Na, et al. Efficacy of serum miR-1273g-3p levels in diagnosis of liver fibrosis in patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 401-404.